Hims & Hers Health
HIMS
$37.57
+8.36%
Hims & Hers Health, Inc. operates a direct-to-consumer telehealth platform that connects patients with healthcare providers for treatment in areas such as erectile dysfunction, hair loss, skincare, mental health, and weight loss, operating within the Medical Equipment & Services industry. The company is a digital-first disruptor, distinguishing itself by offering a vertically integrated model that includes provider networks, pharmacy fulfillment, and personalized care without accepting insurance. The current investor narrative is dominated by the company's aggressive pivot into the weight-loss drug market, highlighted by a recent partnership with Novo Nordisk, which has driven significant stock volatility, while concerns persist over a risky, debt-funded global expansion and the sustainability of its path to profitability amidst slowing revenue growth.…
HIMS
Hims & Hers Health
$37.57
Related headlines
HIMS 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Hims & Hers Health's 12-month outlook, with a consensus price target around $48.84 and implied upside of +30.0% versus the current price.
Average Target
$48.84
1 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
1
covering this stock
Price Range
$30 - $49
Analyst target range
Analyst coverage appears limited with only one firm providing estimates in the dataset, indicating insufficient broad consensus data typically available for a stock of this market cap. The single analyst estimates average EPS of $1.40 and revenue of $4.21 billion, but without a consensus target price or recommendation distribution, it is impossible to gauge overall sentiment or implied upside/downside from the current price. The institutional ratings data shows recent activity with a mix of holds and upgrades following the Novo Nordisk deal in March 2026, including Citigroup and B of A Securities upgrading to Neutral from Sell/Underperform and Needham upgrading to Buy from Hold; however, the wide range of actions (from Buy to Hold) and the lack of a clear target price range signal high uncertainty and low conviction among analysts, which aligns with the stock's highly volatile and speculative profile.
Bulls vs Bears: HIMS Investment Factors
The bull and bear cases for HIMS are sharply divided, with the bear side currently presenting stronger evidence based on fundamentals and valuation. The most compelling bull arguments are momentum-driven and speculative, centered on the transformative Novo Nordisk partnership and a powerful technical rebound. However, the bear case is grounded in concrete financial concerns: a premium valuation demanding flawless execution, decelerating revenue growth, volatile profitability, and a risky, levered balance sheet. The single most important tension in the investment debate is whether the explosive growth potential from the weight-loss drug pivot can sustainably justify and overcome the company's deteriorating profitability metrics and high financial leverage before investor patience runs out.
Bullish
- Explosive Momentum & Technical Reversal: The stock has surged 75.13% over the past 3 months and 34.68% in the past month, breaking out from its 52-week low of $13.74. This powerful move, driven by the Novo Nordisk partnership news, signals a potential trend reversal from a severe downtrend where the stock was down 26.66% over the past year.
- Strong Revenue Growth & High Margins: Q4 2025 revenue grew 28.4% YoY to $617.8M, maintaining a robust growth trajectory. The company boasts an exceptionally high gross margin of 71.9%, providing significant operating leverage as it scales its platform.
- Path to Profitability & Positive FCF: The company is profitable, with Q4 2025 net income of $20.6M and a net margin of 3.3%. It also generates solid free cash flow, with TTM FCF of $72.9M, providing internal funding for its aggressive expansion plans.
- Strategic Novo Nordisk Partnership: The March 2026 deal with Novo Nordisk for weight-loss drugs provides a major growth catalyst and removes a legal overhang. This pivot into the high-demand GLP-1 market is a key driver of the recent stock re-rating and future revenue potential.
Bearish
- Extreme Valuation & High Expectations: The stock trades at a lofty forward P/E of 38.1x and a trailing P/E of 57.0x, a significant premium to the healthcare services sector. This valuation implies the market expects a 33% growth in earnings, leaving no room for execution missteps.
- Slowing Growth & Profitability Volatility: Revenue growth has decelerated sequentially from 48.7% YoY in Q1 2025 to 28.4% in Q4 2025. Concurrently, net income has fallen sharply from $49.5M in Q1 2025 to $20.6M in Q4 2025, indicating margin pressure from expansion investments.
- Risky Debt-Funded Expansion: The company's aggressive global expansion is funded by debt, evidenced by a high debt-to-equity ratio of 2.07. A recent $350M convertible debt offering threatens significant shareholder dilution, as highlighted by recent news causing a stock drop.
- Extreme Volatility & High Beta: With a beta of 2.40, HIMS is 140% more volatile than the market. The stock has experienced a maximum drawdown of -78.06% over the past year, indicating high risk and susceptibility to sharp sell-offs on negative news.
HIMS Technical Analysis
The stock is in a volatile downtrend over the past year, evidenced by a 1-year price change of -26.66%, but has recently experienced a sharp recovery from its lows. Currently trading at $33.94, it sits approximately 48% above its 52-week low of $13.74 but still 52% below its 52-week high of $70.43, indicating it is in the lower-middle portion of its annual range and suggesting a potential value opportunity after a severe correction, though significant overhead resistance remains. Recent momentum has been exceptionally strong but volatile, with a 1-month surge of 34.68% and a 3-month gain of 75.13%, sharply diverging from the longer-term downtrend; this explosive move, which includes a massive spike from around $15 to over $35 in April, signals a potential trend reversal or a powerful short squeeze, though it may be prone to a pullback given its extreme beta of 2.40. Key technical levels are the 52-week low of $13.74 as critical support and the 52-week high of $70.43 as major resistance; a sustained breakout above the recent recovery highs near $35 could target the $40-$50 zone, while a breakdown below $15 would likely revisit the lows, with the stock's beta of 2.40 indicating it is 140% more volatile than the market, necessitating larger position sizing for the inherent risk.
Beta
2.40
2.40x market volatility
Max Drawdown
-78.1%
Largest decline past year
52-Week Range
$14-$70
Price range past year
Annual Return
-21.7%
Cumulative gain past year
| Period | HIMS Return | S&P 500 |
|---|---|---|
| 1m | +35.3% | -1.7% |
| 3m | +96.3% | +13.7% |
| 6m | +12.5% | +9.2% |
| 1y | -21.7% | +20.7% |
| ytd | +12.5% | +9.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HIMS Fundamental Analysis
Revenue growth remains robust but shows signs of sequential deceleration; the most recent quarterly revenue for Q4 2025 was $617.8 million, representing a strong year-over-year growth of 28.4%, however, this marks a slowdown from the 48.7% YoY growth seen in Q1 2025, indicating a normalization from hyper-growth levels as the company scales. The company is profitable on a net income basis, reporting $20.6 million in Q4 2025 with a net margin of 3.3%, and maintains a very healthy gross margin of 71.9%; however, profitability has been inconsistent quarter-to-quarter, with net income declining from $49.5 million in Q1 2025, reflecting increased investments and potentially margin pressure from its expansion into weight-loss therapies. The balance sheet shows elevated financial leverage with a debt-to-equity ratio of 2.07, raising risk concerns, but the company generates solid free cash flow, with TTM FCF of $72.9 million, and maintains good liquidity with a current ratio of 1.90, suggesting it can service its obligations while funding growth, though the recent convertible debt offering adds to dilution worries.
Quarterly Revenue
$617818000.0B
2025-12
Revenue YoY Growth
+0.28%
YoY Comparison
Gross Margin
+0.71%
Latest Quarter
Free Cash Flow
$72858000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HIMS Overvalued?
Given the positive net income of $20.6 million in the latest quarter, the primary valuation metric is the P/E ratio. The trailing P/E is a lofty 56.96x, while the forward P/E is 38.13x; the significant gap between the two implies the market expects a substantial 33% growth in earnings over the next year, pricing in the benefits of the Novo Nordisk partnership and expansion. Compared to sector averages, the stock trades at a significant premium; its forward P/E of 38.1x is well above typical healthcare services multiples, and its P/S ratio of 3.11x also suggests a premium, which may be justified only if the company can sustain its high growth rates and significantly expand its net margins from the current 5.5% level. Historically, the current trailing P/E of 56.96x is below the extreme highs seen in late 2025 (e.g., 89.47x at the end of Q4 2025) but remains elevated compared to its 2024 range, indicating that while some optimism has been priced out after the crash, expectations are still high relative to the company's own history, leaving little room for execution missteps.
PE
57.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -68x~375x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
45.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: HIMS faces significant financial risk from its leveraged balance sheet, with a debt-to-equity ratio of 2.07. Its path to consistent profitability is uncertain, as net income declined from $49.5M in Q1 2025 to $20.6M in Q4 2025 despite revenue growth, indicating margin compression from expansion costs. The company's reliance on a debt-funded global expansion, including a recent $350M convertible note, creates dilution risk and increases financial fragility if growth stalls. Revenue growth deceleration from 48.7% to 28.4% YoY over the past year raises questions about its ability to sustain the hyper-growth priced into its valuation.
Market & Competitive Risks: The stock trades at a severe valuation premium, with a forward P/E of 38.1x well above sector averages, making it highly vulnerable to multiple compression if growth slows or interest rates remain elevated. Its beta of 2.40 indicates extreme sensitivity to broader market swings, and the stock has significantly underperformed the S&P 500 by -45.8% over the past year. Competitive risks are heightened by the weight-loss drug market entry, where generic competition from India (as noted in recent news) could pressure pricing and margins for its new partnership. Regulatory scrutiny on telehealth and drug pricing presents an additional external threat.
Worst-Case Scenario: The worst-case scenario involves a combination of execution missteps on the global expansion, faster-than-expected margin erosion from the weight-loss drug rollout, and a broader market downturn compressing growth stock multiples. This could trigger a loss of investor confidence, leading to a rapid de-rating. The realistic downside is substantial, with the stock potentially revisiting its 52-week low of $13.74, representing a -60% decline from the current price of $33.94. Such a drawdown is plausible given the stock's history of a -78% maximum drawdown and its high volatility profile.